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Abstract
Objective Follow-up after curative resection of colo-
rectal carcinoma (CRC) has been subjected to debate
concerning its effectiveness to reduce cancer mortality.
Current national and international guidelines advise
CEA measurements every 3 months during 3 years after
surgery. The common clinical practice and opinion
about follow-up for colorectal carcinoma, was evaluated
by means of a survey among Dutch general surgeons.
Method A web-based survey of follow-up after treatment
of CRC was sent to all registered Dutch general surgeons.
A reply from 246 surgeons treating patients for colorectal
carcinoma in 105 out of 118 hospitals was received
(response rate 91%). Questions related to actual follow-
up protocol, opinion about serum CEA monitoring, liver
and/or lung metastasectomy, and motivation to partici-
pate in a new trial concerning follow-up.
Results For the majority of surgeons the length of
follow-up was influenced by age of the patient (62%) and
physical condition (76%) prohibiting hepatic metastasec-
tomy. The generally accepted follow-up protocol consis-
ted of CEA measurements every 3 months in the first year
and six-monthly thereafter, and ultrasound examination
of the liver every 6 months. Nearly all surgeons (92%)
were willing to participate in a new study of follow-up
protocol.
Conclusion The adherence to national guidelines for
the follow-up of colorectal carcinoma is low. The
indistinctness about follow-up after curative treatment
of colorectal carcinoma also affects clinical practice.
Recent advancements in imaging techniques, liver and
lung surgery have changed circumstances, which are
not yet anticipated upon in current guidelines.
Renewal of follow-up based upon scientific evidence is
required.
Keywords colorectal neoplasms, oncology, carcino-
embryonic antigen, follow-up
Introduction
There is controversy regarding follow-up after curative
resection of colorectal carcinoma (CRC) regarding its
effectiveness in reducing cancer mortality. No clinical
trial or meta-analysis has unequivocally shown a benefit
on patient survival [1–6]. In the past 30 years, several
attempts have been made to improve survival, either by
advancements in treatment or changing the protocol of
follow-up. Only serum CEA has proven to be of
(limited) value, with consistent results on lead time but
inconsistent results on survival [1,7–17]. Current guide-
lines [18–22] therefore advise CEA measurement every
3 months over 3 years. To detect metachronous second
colorectal malignancy, colonoscopy is advised every
3 years [20]. Dutch guidelines are similar to those
advised by the American Society of Clinical Oncology.
The lack of solid evidence on the benefit of follow-up
has raised the question whether follow-up should be
continued. Technical developments in imaging and
increased use of liver and lung surgery for metastatic
disease outdate present guidelines since they still reflect
the results from studies that were done before these
developments.
A survey was undertaken among Dutch general
surgeons treating patients with colorectal carcinoma to
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assess the opinion on diagnostic methods used in follow-
up, the adherence to national guidelines concerning CEA
measurement, and the treatment of recurrent disease.
The motivation of the respondents to participate in new
studies concerning follow-up was also evaluated.
Method
A request to complete a web-based survey was sent to all
registered general surgeons in the Netherlands (n ¼
878). A reply was received from 246 surgeons treating
patients with colorectal carcinoma from 105 different
hospitals out of a total of 116 hospitals in the Nether-
lands with a surgical department, giving a response rate of
91%.
To detect possible bias through differences in
response rate within hospitals, the outcome was also
calculated using only one representative per hospital. In
comparison with the outcome from all 246 surgeons,
there were no differences.
The survey included 17 questions, with a total of
seven free answers that were categorized afterwards. They
related to the indication for follow up, actual local follow-
up practice, application of serum CEA measurement and
opinion about serum CEA monitoring in follow up. The
use and availability of other diagnostic methods, both for
screening and evaluation of suspected metastases, and
practice concerning treatment of liver and lung metasta-
ses were evaluated. Finally the opinion and feasibility for a
new study, in response to a proposition in the question-
naire, was sought.
Results
Each surgeon treated approximately 30 patients with
CRC per year. The length of follow up was influenced by
age according to 62% (n ¼ 153) and physical condition
prohibiting hepatic metastasectomy according to 76%
(n ¼ 187). Usually after the age of 80 years follow-up
was limited.
In Table 1, the percentage of surgeons who adhered
to a certain follow-up test at a specific moment is given.
In general CEA was measured with a lower intensity than
guideline advice, especially in the second and third year,
and ultrasound was used regularly. Colonoscopy was
regularly done in year 1, 3 and 5 and one-third requested
a yearly chest X-ray.
The majority of surgeons (65%, n ¼ 161) used the
thresholds for the CEA value as suggested in the
questionnaire as follows: CEA < 5 ng/ml: no action,
CEA > 5 < 10 ng/ml: monthly measurement, evaluation
for recurrent disease when CEA is rising, CEA > 10 ng/
ml: evaluation for recurrent disease. CEA was not
measured at all by 6% of respondents, CEA-rise or
doubling time was used by 14%, a lower threshold was
applied by 7% and a higher threshold by 2%. The majority
(67%) chose helical computed tomography (CT) scan-
ning of the chest and abdomen for evaluation of
suspected recurrent disease, followed by positron emis-
sion tomography (PET) scanning when nothing is found
on CT. Ultrasound was added by 11% of surgeons and
colonoscopy by 4%.
A one-third of surgeons (31%) treating colorectal
carcinoma carried out liver resections as well. Analysis of
the opinion concerning the eligibility criteria for hepatic
metastasectomy was done for the whole group and
separately for the liver surgeons. A large majority of all
surgeons (93%) concurred with liver and lung resections
for metastasectomy. A minority (27%) did not consider
liver resection indicated when resectable extrahepatic
disease was present. There is no disagreement on these
two criteria among the general and liver surgeons. Liver
surgeons expressed a different opinion on the eligibil-
ity for hepatic metastasectomy when lymph node
Table 1 Follow-up scheme, current practice.
Year 1 2 3 4 5
Month 3 6 9 12 3 6 9 12 3 6 9 12 6 12 6 12
Physical examination 89 78 50 78 17 72 16 74 3.7 49 4.5 74 30 55 26 66
CEA 63 78 50 83 20 69 20 78 8 47 8 74 28 60 25 67
Ultrasound liver 11 44 10 58 4 36 3.3 56 2 22 2.8 48 8.5 36 7.3 44
Chest X-ray 5 18 5 32 0.4 13 0.4 29 – 8 1.2 26 3.6 19 3.3 25
Colonoscopy 2 7 1.6 65 2 5 – 16 3 2.4 7.7 38 5.3 18 2.8 35
CT abdomen 1.2 2.4 0.4 8 0.4 2.4 0.4 4.5 0.4 1.2 0.4 4.5 0.8 2.4 0.4 3.7
CT thorax – 0.8 0.4 4 0.4 0.8 0.4 0.8 0.4 – 0.4 0.8 0.4 0.8 0.4 0.8
In each box the percentage of surgeons that carries out the examination at that time, is given. All percentages >35% are in italics, all
percentages between 15 and 35% are in bold and beneath 15% are in bold italics.
Follow-up of CRC, survey in the Netherlands I. Grossmann et al.
788  2007 The Association of Coloproctology of Great Britain and Ireland. Colorectal Disease, 9, 787–792
involvement in the hepatoduodenal ligament and bilobar
disease were present. They considered these findings to
be less often a contraindication for surgery (Table 2). The
majority of surgeons (76%) felt that the number of
metastases was not a decisive criterion for metastasecto-
my. When the number of metastases was considered
important, a maximum of three to five was generally
regarded as being amenable to surgery.
Nearly all surgeons (92%) were willing to participate in
a new study concerning follow-up. When imaging was
added to the proposed new follow-up scheme, ultrasound
was preferred above CT scan of the abdomen by general
surgeons. When the results were analysed for surgeons
who also perform liver surgery, CT scanning was
preferred above ultrasound. Generally imaging every
6 months in the first 2 years and every year in years
three, four and five was supported by the respondents
(Table 3). The most important exclusion criteria for
metastasectomy included age and physical condition.
Discussion
The results of this survey are highly representative for the
current follow-up after surgical treatment for patients
with colorectal cancer in the Netherlands. The high
response rate is likely due to the easy accessibility of the
survey on the web, and the present interest in surgery for
metastases. The results of this survey reflect the doubts
and uncertainty in follow-up and treatment options for
recurrent disease.
Age and poor physical condition are the main reasons
which limit follow-up. At least a quarter of surgeons did
not consider that age or physical condition should
limit follow-up. Frequently expressed arguments for
continuing regular outpatient visits include quality con-
trol of surgical treatment and psychosocial considera-
tions. Both arguments are controversial [23–26].
The median time after which recurrent disease is
detected (disease free interval) is approximately 0.5–
2 years for liver metastasis, 2–3 years for lung metastasis
and 0.5–1.5 years for local recurrence [10,11,14,17,27–
29,31–34]. The time after which metastasis or local
recurrence are diagnosed varies with the diagnostic
methods used [14,15,29–32] and the detection of local
recurrence might also be dependent on the site of the
primary tumour (colon or rectum). The common practice
Table 2 Eligibility for hepatic metastasectomy.
All surgeons
(n ¼ 246) (%)
Liver surgeons












Resectable lung metastasis 92.6 88.2
Number of metastasis is
a criterion
23.5 19.7
Table 3 Suggested imaging (all surgeons).
Year 1 2 3 4 5
Month 3 6 9 12 3 6 9 12 3 6 9 12 6 12 6 12
Ultrasound 17 54 14 57 4.9 40 4.1 57 1.6 26 2.4 51 11 35 10 46
Ct abdomen 3.3 27 1.6 50 1.2 22 1.2 42 1.6 7.3 2.0 30 4.1 16 4.1 25
In each cubicle the percentage of surgeons that carries out the examination at that time, is given. All percentages >35% are in italics, all
percentages between 15 and 35% are in bold and beneath 15% are in bold italics.
Table 4 Suggested imaging (liver surgeons).
Year 1 2 3 4 5
Month 3 6 9 12 3 6 9 12 3 6 9 12 6 12 6 12
Ultrasound 19 43 20 32 4.1 26 4.1 39 1.4 22 1.4 30 9.5 23 8.1 28
CT abdomen 4.1 39 1.4 65 1.4 35 1.4 54 1.4 6.8 1.4 28 5.4 15 4.1 20
In each cubicle the percentage of surgeons that carries out the examination at that time, is given. All percentages >35% are in italics, all
percentages between 15 and 35% are in bold and beneath 15% are in bold italics.
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concerning CEA measurement, despite the recommen-
dation in national guidelines, limited the three monthly
measurements to the first year. After that the intensity of
controls diminished to every 6 months or longer. Actual
measurement was often even lower and never more
then 50% for CEA measurement at each moment
(Grossmann I, unpublished results). Thus the present
clinical practice does not anticipate the actual moment
recurrent disease appears. This might lead to missing
more potentially curable recurrent disease than is neces-
sary. The logistic burden of follow-up might be another
reason for the low adherence to guidelines as others have
reported [10,30,35]. Finding effective logistic ways to
ensure adherence to guidelines might enhance the
effectiveness of follow-up.
A further reason to omit CEA from follow-up that was
mentioned by several surgeons in this survey was that a
normal preoperative CEA would mean that it will not rise
when recurrence occurs. This, however, is not valid. A
normal preoperative CEA is present in approximately 50%
of all patients with rectal carcinoma, and 50% will rise
with recurrent disease. Thus 25% will miss a chance
of early detection when CEA follow-up is omitted
(I. Grossmann e.a., EJSO 2007; 33: 183–187).
A majority of surgeons added ultrasound as a screen-
ing tool in their follow-up, though this was not included
in the national guidelines. This may be because one
regional guideline advises ultrasound when preoperative
CEA is normal. Another reason might be low confidence
in the value of CEA as a tumour marker, and the
increasing confidence in imaging. In recent years major
advances have been made in imaging. The present multi-
slice helical CT scan can detect liver and lung metastasis
when its diameter exceeds approximately 0.5 cm. It is
feasible therefore to localize recurrent disease in lung and
liver as soon as CEA exceeds its threshold [15,27,36].
Thus a major problem in the past has finally been solved.
When CEA rises, recurrent disease can nowadays usually
be localized and, where feasible, treatment can be
initiated immediately. The ability of ultrasound examina-
tion to detect liver metastasis is less sensitive. Evaluation
is limited to the liver, while lung metastases are also
frequently curable. Considering this, the role of regular
hepatic ultrasound in follow-up is questionable when
helical CT scanning of thorax and abdomen is available
instead. The frequency of performing a CT scan however,
is limited by availability, cost and the potential health risk
of radiation exposure.
More patients seem eligible for surgical treatment of
metastatic disease than appear to be eligible in the
Netherlands. Uncertainty exists regarding the criteria for
liver resection for metastasis, as also shown in another
recent Dutch survey [37]. The difference of opinion
between liver surgeons and general surgeons on some
criteria might be an expression of this finding. In the last
10 years many criteria, that were previously considered
contra-indications for metastasectomy, are now being
debated. Among these criteria are age, number and
localization of metastasis, presence of resectable extrahe-
patic disease and previous metastasectomy. The increas-
ing safety and technical advancements have resulted in
more older patients becoming candidates for metastasec-
tomy. Furthermore, many patients with disseminated
colorectal carcinoma are relatively young at 60–65 years.
The number and involvement of multiple segments of
both liver and lung are not contraindications, provided
they are completely resectable [32,34,38–41] although
the Dutch general surgeons in the survey often consid-
ered the metastasis count of liver metastasis (23.5%) and
bilobar involvement (18%) to prohibit resection. Resec-
tion of synchronous or metachronous lung metastases
may result in long-term survival equal to resectable
metastasis confined to only one organ [33,34,42–44].
Among the Dutch surgeons 8–12% did not consider
these patients eligible for surgery. Re-resection of meta-
stases of both lung and liver result in near equal survival
rates as after the first metastasectomy [32,34,39–45]. The
differences in opinion regarding eligibility for hepatic
metastasectomy indicate ongoing advances in liver sur-
gery, which allow more patients to be a candidate for
curative surgery. The same appears to be true for lung
metastasis.
There is considerable controversy about follow-up
after curative treatment of colorectal carcinoma because it
has thus far not been proven to increase survival or quality
of life. Meanwhile, recent rapid technical developments in
imaging and advances in liver and lung surgery have
changed the circumstances. Review of the guidelines on
follow-up to reflect these changes is required. The high
motivation among Dutch surgeons to participate in a new
study appears to support this, making a national trial
feasible.
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